<aside>
This page summarises the most important evidence we currently have on IMPALA’s impact. The strongest evidence currently comes from paediatric implementation and cost-effectiveness studies in Malawi, supported by usability studies, qualitative research, pilot evaluations, and ongoing real-world evidence from additional hospitals.
Start with the four sections below for a quick overview of IMPALA’s evidence on clinical outcomes, healthcare workers, caregivers, and health-system value.
Open each toggle to see the most important findings, key numbers, and remaining evidence gaps.
For a more detailed claim-by-claim overview, see the Evidence Summary Dashboard, which maps each impact claim to its evidence sources, evidence strength, and remaining evidence gaps.
</aside>
<aside> <img src="/icons/first-aid_green.svg" alt="/icons/first-aid_green.svg" width="40px" />
</aside>
<aside> <img src="/icons/cash_green.svg" alt="/icons/cash_green.svg" width="40px" />
</aside>
<aside> <img src="/icons/sharing_green.svg" alt="/icons/sharing_green.svg" width="40px" />
</aside>
<aside> <img src="/icons/meeting_green.svg" alt="/icons/meeting_green.svg" width="40px" />
</aside>
<aside>
</aside>
The current evidence suggests that IMPALA can contribute to improved clinical outcomes, better prioritisation by healthcare workers, more structured caregiver involvement, and meaningful health gains at relatively low cost. The strongest evidence currently comes from paediatric implementation and cost-effectiveness studies in Malawi and Rwanda, where IMPALA was associated with lower mortality, fewer critical illness events, reduced monitoring time, and low cost per admitted child. Evidence from neonatal settings, caregiver engagement, and broader health-system effects is promising but still being strengthened through ongoing implementation, monitoring, and future controlled studies.
<aside>
</aside>